• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 424B5 filed by Cytosorbents Corporation

    7/26/24 5:11:21 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care
    Get the next $CTSO alert in real time by email
    424B5 1 tm2420077d2_424b5.htm 424B5

     

    Filed Pursuant to Rule 424(b)(5)

    Registration No. 333-257910

    AMENDMENT NO. 1 DATED July 26, 2024

    to Prospectus Supplement dated December 30, 2021

    (To Prospectus dated July 27, 2021)

     

     

     

    Up to $19,700,000

    Common Stock

     

     

    This Amendment No. 1 to Prospectus Supplement (this “Amendment”) amends our prospectus supplement dated December 30, 2021 (the “ATM Prospectus Supplement”). This Amendment should be read in conjunction with the ATM Prospectus Supplement and the accompanying prospectus dated July 27, 2021 (File No. 333-257910) (the “Prospectus”), and is qualified by reference thereto, except to the extent that the information herein amends or supersedes the information contained in the ATM Prospectus Supplement or the Prospectus. This Amendment is not complete without, and may only be delivered or utilized in connection with, the ATM Prospectus Supplement and the Prospectus, and any future amendments or supplements thereto.

     

    We previously entered into an Open Market Sale AgreementSM with Jefferies LLC (“Jefferies”), dated December 30, 2021 (the “Sales Agreement’), relating to shares of our common stock, par value $0.001 per share, offered pursuant to the ATM Prospectus Supplement and the Prospectus. In accordance with the terms of the Sales Agreement, pursuant to the ATM Prospectus Supplement and the Prospectus, we may offer and sell shares of our common stock having an aggregate offering price of up to $25,000,000 from time to time through Jefferies acting as our sales agent. As of June 30, 2024, we have offered and sold 2,709,754 shares of our common stock pursuant to the Sales Agreement for gross proceeds of $4,227,173. Consequently, up to $20,272,827 remains available under the ATM Prospectus Supplement and the Prospectus.

     

    Our common stock is listed on the Nasdaq Global Market under the symbol “CTSO.” The last reported sale price of our common stock on July 25, 2024 was $1.03 per share.

     

    On March 15, 2024, the date we filed our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, we became subject to the offering limits in General Instruction I.B.6 of Form S-3. We are filing this Amendment to amend the ATM Prospectus Supplement to update the amount of shares of our common stock we are eligible to sell under General Instruction I.B.6 of Form S-3 and pursuant to the Sales Agreement. The aggregate market value of our outstanding common stock held by non-affiliates, also known as our public float, is $59,111,703, based on 52,778,307 shares of our outstanding common stock held by non-affiliates as of June 30, 2024 and a price of $1.12 per share, the closing price of our common stock on July 16, 2024, which is within 60 days of the date of this Amendment. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell shares of our common stock pursuant to the ATM Prospectus Supplement and the Prospectus, as amended by this Amendment, with a value of more than one-third of our public float in any 12-month period, so long as our public float is less than $75,000,000. As of the date of this Amendment, we have not offered and sold any shares of our common stock pursuant to General Instruction I.B.6 to Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof.

     

    As a result of these limitations and the current public float of our common stock, and in accordance with the terms of the Sales Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to approximately $19,700,000 from time to time through Jefferies. If our public float increases above $75,000,000 such that we may sell additional amounts under the Sales Agreement, the ATM Prospectus Supplement and the Prospectus, we will file another amendment to the ATM Prospectus Supplement prior to making additional sales in excess of $19,700,000.

     

    Investing in our common stock involves a high degree of risk. Before making an investment decision, please read the information under the heading “Risk Factors” beginning on page S-9 of the ATM Prospectus Supplement and in the Prospectus and the documents incorporated by reference therein.

     

    Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this Amendment, the ATM Prospectus Supplement or the Prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

     

     

    Jefferies

     

    The date of this Amendment No. 1 to ATM Prospectus Supplement is July 26, 2024.

     

     

     

    Get the next $CTSO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CTSO

    DatePrice TargetRatingAnalyst
    9/7/2023$4.00Buy
    B. Riley Securities
    10/14/2021$10.00Buy
    B. Riley Securities
    More analyst ratings

    $CTSO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Mariani Peter J bought $19,294 worth of shares (20,000 units at $0.96), increasing direct ownership by 5% to 401,363 units (SEC Form 4)

    4 - Cytosorbents Corp (0001175151) (Issuer)

    12/16/24 7:00:11 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Mariani Peter J bought $27,975 worth of shares (31,363 units at $0.89), increasing direct ownership by 9% to 381,363 units (SEC Form 4)

    4 - Cytosorbents Corp (0001175151) (Issuer)

    12/13/24 8:00:13 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    Sobel Alan D. bought $30,001 worth of shares (22,557 units at $1.33), increasing direct ownership by 28% to 101,857 units (SEC Form 4)

    4 - Cytosorbents Corp (0001175151) (Issuer)

    12/15/23 4:35:14 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    $CTSO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update

    Fourth quarter and Full-Year 2025 revenue are expected to be approximately $9.2 million and $37.0 million, respectively, with expected Q4 gross margins in the range of 73% to 75% DrugSorb®-ATR De Novo Pre-Submission Meeting scheduled with the FDA this month, with anticipated De Novo Application filing this quarter and regulatory decision in mid-2026 Results of the pivotal STAR-T study for DrugSorb®-ATR have recently been accepted for publication in a top cardiac surgery journal Management will host in-person investor meetings in San Francisco during J.P. Morgan Healthcare Conference week PRINCETON, N.J., Jan. 12, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the tr

    1/12/26 7:00:00 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025

    PRINCETON, N.J., Dec. 10, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that Dr. Phillip Chan, CEO, and Peter J. Mariani, CFO, will join Jason Kolbert, Head of Healthcare Research at D. Boral Capital, for a virtual fireside chat. Building on the Company's recent third quarter earnings call, highlighting $37.0 million in trailing 12-month high-margin sales, a strengthened balance sheet, and ongoing regulatory progress for DrugSorb™-ATR with the U.S. Food and Drug Administration (FDA) and a key regulatory decision expected in mid-2026,

    12/10/25 7:00:00 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London

    PRINCETON, N.J., Nov. 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in one-on-one meetings with investors at the Jefferies Global Healthcare Conference, being held on November 17-20, 2025 in London, United Kingdom. CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents' flagship product, CytoSorb(R), is approved in the Euro

    11/17/25 5:42:00 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    $CTSO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Chan Phillip P. was granted 100,000 shares, increasing direct ownership by 7% to 1,482,963 units (SEC Form 4)

    4 - Cytosorbents Corp (0001175151) (Issuer)

    11/20/25 9:09:45 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Chan Phillip P. was granted 105,600 shares, increasing direct ownership by 8% to 1,382,963 units (SEC Form 4)

    4 - Cytosorbents Corp (0001175151) (Issuer)

    8/8/25 7:40:26 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Jones Edward Raymond

    4 - Cytosorbents Corp (0001175151) (Issuer)

    8/8/25 7:39:21 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    $CTSO
    SEC Filings

    View All

    Cytosorbents Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Cytosorbents Corp (0001175151) (Filer)

    11/13/25 4:34:39 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Cytosorbents Corporation

    10-Q - Cytosorbents Corp (0001175151) (Filer)

    11/13/25 4:32:19 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    Cytosorbents Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Cytosorbents Corp (0001175151) (Filer)

    10/3/25 4:20:54 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    $CTSO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on CytoSorbents with a new price target

    B. Riley Securities initiated coverage of CytoSorbents with a rating of Buy and set a new price target of $4.00

    9/7/23 8:13:32 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    B. Riley Securities resumed coverage on CytoSorbents with a new price target

    B. Riley Securities resumed coverage of CytoSorbents with a rating of Buy and set a new price target of $10.00

    10/14/21 7:58:45 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    $CTSO
    Financials

    Live finance-specific insights

    View All

    CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update

    Third quarter 2025 revenue of $9.5 million, up 10% year-over-yearAmended credit agreement with Avenue Capital Group which strengthens our balance sheet with an additional $2.5 million of cash, and extends the interest only-period through December 31, 2026, with an additional $2.5 million available and an additional extension of the interest-only period to June 30, 2027 with DrugSorb-ATR FDA marketing approvalImplemented Workforce and Cost Reduction Program to accelerate path to cash-flow breakeven to Q1 2026Submitted DrugSorb™-ATR De Novo pre-submission package to FDA, with meeting expected in Q4 2025 or early Q1 2026, followed by planned submission of new De Novo application in Q1 2026, and

    11/13/25 4:05:00 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights

    PRINCETON, N.J., Oct. 30, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report third quarter 2025 financial results and recent business highlights after the market close on Thursday, November 13, 2025. CTSO) is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification. CytoSorbents' flagship product, CytoSorb(R), is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents i

    10/30/25 7:00:00 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    CytoSorbents Reports Second Quarter 2025 Financial Results and Provides Business Update

    PRINCETON, N.J., Aug. 7, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the second quarter ended June 30, 2025, and recent business highlights.  CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, CytoSorb®, is approved in the European Union and distributed in over 70 countries worldwide. CytoSorbents is conducting trials to support FDA marketing approval of DrugSorb™-ATR for

    8/7/25 4:00:00 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    $CTSO
    Leadership Updates

    Live Leadership Updates

    View All

    CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller

    Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., April 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Melanie Grossman, CPA as Vice President and Corporate Controller.  Ms. Grossman joins CytoSorbents with over 25 years of accomplished finance and accounting experience in global, publicly-traded companies. 

    4/17/25 7:00:00 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America

    PRINCETON, N.J., April 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Thomas Shannon as Vice President of Marketing for North America. With anticipated marketing approval, Mr. Shannon will lead the marketing strategy and execution for DrugSorb™-ATR in the U.S. and Canada. CTSO) is a leader in the treatment of life-threatening conditions using blood purification. CytoSorbents' flagship product, CytoSorb®, is approved in the European Union and di

    4/14/25 7:00:00 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    CytoSorbents And Converge Biotech Announce Strategic Partnership to Expand Sepsis and Critical Care Treatment with CytoSorb in India

    PRINCETON, N.J. and HYDERABAD, India, Nov. 11, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ:CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit (ICU) and during cardiac surgery through blood purification, and Converge Biotech, a prominent healthcare company with a strong critical care and infectious disease focus in India, are pleased to announce a new strategic collaboration where the two companies seek to expand their combined market reach in the sepsis and critical care markets in India with a broad synergistic product portfolio. CytoSorbents is renowned for its flagship product, CytoSorb®, a blood purification technology that red

    11/11/24 7:30:00 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    $CTSO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Cytosorbents Corporation

    SC 13G/A - Cytosorbents Corp (0001175151) (Subject)

    11/14/24 4:48:32 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Cytosorbents Corporation

    SC 13G - Cytosorbents Corp (0001175151) (Subject)

    2/14/24 4:42:32 PM ET
    $CTSO
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Cytosorbents Corporation

    SC 13G - Cytosorbents Corp (0001175151) (Subject)

    2/14/24 9:00:04 AM ET
    $CTSO
    Medical/Dental Instruments
    Health Care